nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

28.11.2023 | Editorial

Why chose nuclear medicine: the journey of two medical imaging students in China

verfasst von: Zaijie Wu, Yueling Deng, Xiaotian Xia, Xiaoli Lan

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Excerpt

We are pleased to share our journey and the reasons behind choosing nuclear medicine for our advanced academic and professional endeavors. As undergraduate students in medical imaging from China, we are enthusiastic about commencing our Master’s degree program at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. …

Chiti A. Celebrating EJNMMI 50th volume. Eur J Nucl Med Mol Imaging. Published online August 3, 2023. https://doi.org/10.1007/s00259-023-06368-0.

Titel: Why chose nuclear medicine: the journey of two medical imaging students in China
verfasst von: Zaijie Wu
Yueling Deng
Xiaotian Xia
Xiaoli Lan
Publikationsdatum: 28.11.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06541-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Why chose nuclear medicine: the journey of two medical imaging students in China

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Abdelhamid H. Elgazzar, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition

New opportunities for dosimetric approach in patients with differentiated thyroid cancer

Letter to the editor concerning “Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor”

The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy

Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group

Diagnostic accuracy of anti-3-[18F]-FACBC PET/MRI in gliomas